Ceralasertib clinical trials
Also written AZD6738.
ClinicalTrials.gov finds 47 studies for ceralasertib. How that becomes 46 here
Every study that search finds has been read, to see whether and how it gives ceralasertib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 47Found by its intervention search · See all 47 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 31 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 47Give ceralasertib to participants
- −1Give it beside what is tested
- 46Test it: the count on this site
Get an email when these change. Save the ceralasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 7 |
| 2019 | 8 |
| 2020 | 8 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 30
AstraZeneca (14) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Institute of Cancer Research, United Kingdom (3) · M.D. Anderson Cancer Center (2) · Acerta Pharma BV (2) · Seoul National University Hospital (2) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Olaparib (7) · Durvalumab (5) · Adavosertib (4) · Capivasertib (4) · Vistusertib (3) · AZD 6244 (3) · Danvatirsen (2) · Oleclumab (2)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 1 most studied
New when their studies opened, with ceralasertib beside them; studies of each.
Reaching primary completion within a year · 4
Studies that test ceralasertib.
- Dec 2026PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerPhase 2 · Institute of Cancer Research, United Kingdom
- Dec 2026Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerPhase 2 · M.D. Anderson Cancer Center
- Jan 2027Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerPhase 2 · Muhammad Furqan
- Mar 2027Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialPhase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses ceralasertib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 46
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567With olaparib in BRCA-mutated breast cancerWritten as CeralasertibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135With olaparib in one arm, children with relapsed tumoursWritten as CeralasertibReport a problem
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Added to durvalumab in one biomarker cohort, small cell lung cancerWritten as CeralasertibReport a problem
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104With radiotherapy and then durvalumab in one arm, lung cancerWritten as CeralasertibReport a problem
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingPhase 2Mario Negri Institute for Pharmacological ResearchNCT06680050With durvalumab after re-irradiation in relapsed stage III lung cancerWritten as CeralasertibReport a problem
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingPhase 2IFOM ETS - The AIRC Institute of Molecular OncologyNCT05582538Given first, then with durvalumab and nab-paclitaxel, in triple-negative breast cancerWritten as CeralasertibReport a problem
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingPhase 2Institute of Cancer Research, United KingdomNCT03740893Alone before surgery in triple-negative breast cancerWritten as AZD6738Report a problem
- AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingPhase 2Seoul National University HospitalNCT04298008With durvalumab in biliary tract cancerWritten as AZD6738Report a problem
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03878095With olaparib in IDH-mutant tumoursWritten as CeralasertibReport a problem
- A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)Active, not recruitingPhase 2Samsung Medical CenterNCT03780608With durvalumab in gastric cancer or melanomaWritten as AZD6738Report a problem
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04704661With trastuzumab deruxtecan in HER2-expressing tumoursWritten as CeralasertibReport a problem
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerCompletedPhase 2University of PennsylvaniaNCT03462342With olaparib in recurrent ovarian cancerWritten as AZD6738Report a problem
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingPhase 2AstraZenecaNCT03330847With olaparib, against olaparib alone, in breast cancerWritten as Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Report a problem
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingPhase 1Massachusetts General HospitalNCT03770429Alone in MDS or CMMLWritten as AZD6738Report a problem
- Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04417062With olaparib in recurrent osteosarcomaWritten as CeralasertibReport a problem
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT06732401Added to durvalumab after surgery for lung cancerWritten as CeralasertibReport a problem
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingPhase 2AstraZenecaNCT05941897With durvalumab in lung cancer after PD-1 therapyWritten as CeralasertibReport a problem
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingPhase 2Muhammad FurqanNCT04699838With durvalumab as maintenance after chemo-immunotherapy, small cell lung cancerWritten as CeralasertibReport a problem
- Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminatedPhase 1AstraZenecaNCT06754761Radiolabelled dose to trace how the body handles itWritten as [14C] AZD6738Report a problem
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingPhase 1AstraZenecaNCT05514132With durvalumab, dose finding in Chinese patientsWritten as CeralasertibReport a problem
See all 46 studies that test ceralasertib →
Tested on its own · 4 — no other medicine in its arm
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingPhase 1Massachusetts General HospitalNCT03770429Alone in MDS or CMMLWritten as AZD6738Report a problem
- A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerCompletedPhase 2AstraZenecaNCT04564027Alone in ATM-altered tumoursWritten as CeralasertibReport a problem
- Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid TumoursStatus unknownPhase 1Royal Marsden NHS Foundation TrustNCT02223923Alone and with radiotherapy, first dose-finding studyWritten as AZD6738Report a problem
- An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT05469919Alone, dose finding in Japanese patientsWritten as CeralasertibReport a problem
Tested with established drugs · 24 — they are given beside it
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingPhase 2SWOG Cancer Research NetworkNCT06769126Added to durvalumab in one biomarker cohort, small cell lung cancerWritten as CeralasertibReport a problem
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingPhase 2Mario Negri Institute for Pharmacological ResearchNCT06680050With durvalumab after re-irradiation in relapsed stage III lung cancerWritten as CeralasertibReport a problem
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingPhase 2IFOM ETS - The AIRC Institute of Molecular OncologyNCT05582538Given first, then with durvalumab and nab-paclitaxel, in triple-negative breast cancerWritten as CeralasertibReport a problem
- AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingPhase 2Seoul National University HospitalNCT04298008With durvalumab in biliary tract cancerWritten as AZD6738Report a problem
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03878095With olaparib in IDH-mutant tumoursWritten as CeralasertibReport a problem
- A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)Active, not recruitingPhase 2Samsung Medical CenterNCT03780608With durvalumab in gastric cancer or melanomaWritten as AZD6738Report a problem
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04704661With trastuzumab deruxtecan in HER2-expressing tumoursWritten as CeralasertibReport a problem
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerCompletedPhase 2University of PennsylvaniaNCT03462342With olaparib in recurrent ovarian cancerWritten as AZD6738Report a problem
- Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT04417062With olaparib in recurrent osteosarcomaWritten as CeralasertibReport a problem
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT06732401Added to durvalumab after surgery for lung cancerWritten as CeralasertibReport a problem
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingPhase 2AstraZenecaNCT05941897With durvalumab in lung cancer after PD-1 therapyWritten as CeralasertibReport a problem
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingPhase 2Muhammad FurqanNCT04699838With durvalumab as maintenance after chemo-immunotherapy, small cell lung cancerWritten as CeralasertibReport a problem
- Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminatedPhase 1AstraZenecaNCT06754761Radiolabelled dose to trace how the body handles itWritten as [14C] AZD6738Report a problem
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingPhase 1AstraZenecaNCT05514132With durvalumab, dose finding in Chinese patientsWritten as CeralasertibReport a problem
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 1Acerta Pharma BVNCT03328273With acalabrutinib in relapsed CLLWritten as CeralasertibReport a problem
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingPhase 3AstraZenecaNCT05450692With durvalumab, against docetaxel, in lung cancer after PD-1 therapyWritten as CeralasertibReport a problem
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingPhase 2Rahul AggarwalNCT03682289Alone or with olaparib or durvalumab in solid tumoursWritten as CeralasertibReport a problem
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingPhase 2University of Michigan Rogel Cancer CenterNCT03787680With olaparib in castration-resistant prostate cancerWritten as AZD6738Report a problem
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingPhase 2Institute of Cancer Research, United KingdomNCT04065269Alone or with olaparib or durvalumab in gynaecological cancersWritten as CeralasertibReport a problem
- A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingPhase 2AstraZenecaNCT05061134Alone or with durvalumab in melanoma after PD-1 therapyWritten as CeralasertibReport a problem
Showing 20 of 24. See all 24 →
Tested in a combination · 16 — another drug in the study is under test too
- Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04090567With olaparib in BRCA-mutated breast cancerWritten as CeralasertibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135With olaparib in one arm, children with relapsed tumoursWritten as CeralasertibReport a problem
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingPhase 1University of LeedsNCT04550104With radiotherapy and then durvalumab in one arm, lung cancerWritten as CeralasertibReport a problem
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingPhase 2Institute of Cancer Research, United KingdomNCT03740893Alone before surgery in triple-negative breast cancerWritten as AZD6738Report a problem
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingPhase 2AstraZenecaNCT03330847With olaparib, against olaparib alone, in breast cancerWritten as Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Report a problem
- A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug ZTerminatedPhase 1AstraZenecaNCT06929260Its effect on three other drugs' levelsWritten as CeralasertibReport a problem
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03579316With olaparib in one arm, recurrent ovarian cancerWritten as CeralasertibReport a problem
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935With durvalumab in one arm of a lung cancer matrix trialWritten as AZD6738Report a problem
- AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedPhase 2Gordon Mills, MD, PhDNCT03801369Alone in one arm, metastatic triple-negative breast cancerWritten as CeralasertibReport a problem
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingPhase 2AstraZenecaNCT03334617Alone or with durvalumab after PD-1 or PD-L1 therapy in lung cancerWritten as CeralasertibReport a problem
- A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedPhase 2AstraZenecaNCT02937818With olaparib in one arm, platinum-refractory small cell lung cancerWritten as AZD6738 and olaparibReport a problem
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingPhase 2Assistance Publique Hopitaux De MarseilleNCT03833440With durvalumab in one arm, lung cancer after PD-1 therapyWritten as Ceralasertib (AZD6738)Report a problem
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147With acalabrutinib in aggressive lymphomaWritten as AZD6738Report a problem
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedPhase 1AstraZenecaNCT03022409Alone before surgery in head and neck cancer, for biomarkersWritten as CeralasertibReport a problem
- A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnPhase 2AstraZenecaNCT04239014With olaparib as a second maintenance in ovarian cancerWritten as CeralasertibReport a problem
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownPhase 2Institute of Cancer Research, United KingdomNCT03182634With olaparib in one cohort, advanced breast cancerWritten as AZD6738Report a problem
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with ceralasertib: capivasertib 1
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Codes
What other systems call ceralasertib · ClinicalTrials.gg INT000556
- MeSH (NLM) C000611951ceralasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 85RE35306ZCERALASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27896182ceralasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C111993CeralasertibOne source FDA
- DrugBank DB14917One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611951 | ceralasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 85RE35306Z | CERALASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896182 | ceralasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C111993 | Ceralasertib | One source FDA |
| DrugBank | DB14917 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.